Evaluation of N6 Sound Processor in Group of Freedom Users
Launched by COCHLEAR · Aug 4, 2016
Trial Information
Current as of June 18, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects with sensorineural hearing loss
- • 12 years of age and older
- • Currently using Freedom Sound Processor
- • Recipient of a Ci22M or CI24 series implant
- • Minimum of 3 months experience with Freedom Sound Processor
- • Prior documentation of sentence recognition in noise at a +10 SNR or better
- • Native English speaker
- • Willingness to participate and comply with requirements of protocol
- Exclusion Criteria:
- • Unable to complete test metrics
- • Unrealistic expectations regarding possible benefits
- • Additional handicaps that would prevent or restrict participation in audiological evaluations
- • ABI cochlear implant recipient
About Cochlear
Cochlear Limited is a global leader in implantable hearing solutions, dedicated to transforming the lives of individuals with hearing loss through innovative technology and comprehensive clinical research. With a strong commitment to advancing auditory rehabilitation, Cochlear conducts rigorous clinical trials aimed at evaluating the safety and efficacy of its products, including cochlear implants and bone conduction devices. The company collaborates with healthcare professionals and research institutions worldwide to ensure that its solutions meet the highest standards of quality and performance, ultimately enhancing patient outcomes and promoting accessibility to hearing health care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Lori O'Neil, Au.D
Study Director
Cochlear
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials